{"id":972174,"date":"2026-06-15T12:31:50","date_gmt":"2026-06-15T16:31:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/"},"modified":"2026-06-15T12:31:50","modified_gmt":"2026-06-15T16:31:50","slug":"eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/","title":{"rendered":"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc."},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, June  15, 2026  (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (\u201cElicio\u201d or the \u201cCompany\u201d) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P trial for the pancreatic cancer therapy ELI-002 7P missed its primary endpoint. The price of the Company\u2019s stock dropped following this news.<\/p>\n<p align=\"justify\">If you purchased Elicio stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A39HcykjTvXUzuCgttTKuxa9mNZum4zQG9H_bobBQ25Y7Xmr8K9EbAtRqpsIyt-u8VPc2ZHeWfhUQ5qYXTJYUdcfUVRIQYmb67-Rf7c5pJI=\" rel=\"nofollow\" target=\"_blank\"><u>cholzer@holzerlaw.com<\/u><\/a> or Joshua Karr, Esq. at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gfAtc3pmGc_pAk-k2tGXh7VLWCjTcFJHblI9BezXXaKL6vnSTcgYsM8AAv-Br24GeUmFKh99ysAvm4WUFHp9XoE-R7lkaIgWQOcXv1nGnfI=\" rel=\"nofollow\" target=\"_blank\"><u>jkarr@holzerlaw.com<\/u><\/a>, call our toll-free number at (888) 508-6832, or visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TrNKQk9WxkcrZ9b2GKgRJIjcOPNs_l4ktU-D84L6WOKTUUTOGOFP5Z-9pwTs12vbtMY-7DVJK8t0SodBR4nBcv3jZiRfvIUKoIMGqqK2lMZfEddj1AGZS4PFqaoaEJIwXocb1M1KLIFByuntLRbikqfvK3A1-SgtQ3FrX_FUW4A=\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com\/case\/elicio-therapeutics\/<\/a> to discuss your legal rights.<\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website,\u202fwww.holzerlaw.com,\u202fand upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.<\/p>\n<p align=\"justify\">CONTACT:<br \/>Corey Holzer, Esq.\u00a0<br \/>(888) 508-6832 (toll-free)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A39HcykjTvXUzuCgttTKuxa9mNZum4zQG9H_bobBQ27pBiKWRo6rX71kES3n1lHfBr0KQY4tndN-N-2Lj1qmZdD88sK70k2j8va83ufrhqo=\" rel=\"nofollow\" target=\"_blank\"><u>cholzer@holzerlaw.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjgxZTczYTMtZjg1ZS00NjYzLThmY2UtODFhYjMxYWRhYmZkLTExOTIzMzYtMjAyNi0wNi0xNS1lbg==\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (\u201cElicio\u201d or the \u201cCompany\u201d) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P trial for the pancreatic cancer therapy ELI-002 7P missed its primary endpoint. The price of the Company\u2019s stock dropped following this news. If you purchased Elicio stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/elicio-therapeutics\/ to discuss your legal rights. Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-972174","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (\u201cElicio\u201d or the \u201cCompany\u201d) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P trial for the pancreatic cancer therapy ELI-002 7P missed its primary endpoint. The price of the Company\u2019s stock dropped following this news. If you purchased Elicio stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/elicio-therapeutics\/ to discuss your legal rights. Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, &hellip; Continue reading &quot;ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T16:31:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc.\",\"datePublished\":\"2026-06-15T16:31:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/\"},\"wordCount\":237,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/\",\"name\":\"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=\",\"datePublished\":\"2026-06-15T16:31:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/","og_locale":"en_US","og_type":"article","og_title":"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc. - Market Newsdesk","og_description":"ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (\u201cElicio\u201d or the \u201cCompany\u201d) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P trial for the pancreatic cancer therapy ELI-002 7P missed its primary endpoint. The price of the Company\u2019s stock dropped following this news. If you purchased Elicio stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/elicio-therapeutics\/ to discuss your legal rights. Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, &hellip; Continue reading \"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-15T16:31:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc.","datePublished":"2026-06-15T16:31:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/"},"wordCount":237,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/","name":"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=","datePublished":"2026-06-15T16:31:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzExMiM3NjYyMTI3IzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eltx-investor-alert-holzer-holzer-llc-investigation-of-elicio-therapeutics-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ELTX INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Elicio Therapeutics, Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=972174"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972174\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=972174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=972174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=972174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}